Literature DB >> 19485949

Micophenolat Mofetil versus Azathioprine: effects on renal graft function in early posttransplant period.

Farid Ljuca1, Semir Imamović, Deso Mesić, Sefik Hasukić Hasukić, Safet Omerović, Mustafa Bazardzanović, Fatima Iljazagić-Halilović.   

Abstract

All conventional immunosuppressive tree drugs-protocols are based on Cyclosporine; consisting of low doses of Cyclosporine (CsA), Azathioprine (AZA) or Mycophenolate Mofetil (MMF) and Prednisolone. AZA has been used in clinical transplantation for more than 30 years and was the first immunosuppressive agent to achieve widespread use in organ transplantation. MMF was introduced in clinical practice in 1995 after several clinical trials proved that it was more efficient than AZA for prevention of acute rejection episodes. Our aim was to evaluate influence of AZA and MMF on renal graft function in early post-transplant stage. Study recruited 74 patients who underwent kidney transplantation in University Clinical Centre Tuzla. All patients received CsA and corticosteroid-based immunosuppression, as a part of triple immunosuppressive regiment, 40 patients received AZA and 34 MMF. In order to assess renal graft function, following parameters were evaluated: glomerular filtration rate GFR (ml/min) creatinine clearance (CrCl) (ml/min), 24 h urine output (ml/day), and from the serum potassium, sodium, urea and creatinine (mmol/dm3). Significantly higher average values of 24 hour urine output were recorded during first seven postoperative days in patients receiving MMF compared to those treated with AZA. Serum creatinine values showed statistically significant decrease, starting with the second postoperative day, in MMF vs. AZA group (168,7+/-70,5 vs. 119,9+/-42,6; p<0,0007). GFR was significantly higher in MMF compared to the AZA group of patients. On the first post-transplant day CrCl was higher in AZA group (24,3+/-10 vs. 17,5+/-7,3; p=0,01), next six days situation is reversed CrCl is significantly higher in the MMF group (43,7+/-15 vs. 53, 4+/-22, 8 p=0,006). MMF vs. AZA therapy was associated with protective effect against worsening of renal function in first seven post-transplant days.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19485949      PMCID: PMC5638221          DOI: 10.17305/bjbms.2009.2836

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  24 in total

Review 1.  Immunosuppressive drugs for kidney transplantation.

Authors:  Philip F Halloran
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

Review 2.  Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy.

Authors:  W M Bennett; A DeMattos; M M Meyer; T Andoh; J M Barry
Journal:  Kidney Int       Date:  1996-10       Impact factor: 10.612

Review 3.  Cyclosporine nephrotoxicity.

Authors:  B D Myers
Journal:  Kidney Int       Date:  1986-12       Impact factor: 10.612

4.  A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

Authors:  J Kobashigawa; L Miller; D Renlund; R Mentzer; E Alderman; R Bourge; M Costanzo; H Eisen; G Dureau; R Ratkovec; M Hummel; D Ipe; J Johnson; A Keogh; R Mamelok; D Mancini; F Smart; H Valantine
Journal:  Transplantation       Date:  1998-08-27       Impact factor: 4.939

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.

Authors:  P Halloran; T Mathew; S Tomlanovich; C Groth; L Hooftman; C Barker
Journal:  Transplantation       Date:  1997-01-15       Impact factor: 4.939

7.  Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection.

Authors:  A O Ojo; H U Meier-Kriesche; J A Hanson; A B Leichtman; D Cibrik; J C Magee; R A Wolfe; L Y Agodoa; B Kaplan
Journal:  Transplantation       Date:  2000-06-15       Impact factor: 4.939

8.  Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.

Authors: 
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

9.  CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.

Authors:  Imke Tiede; Gerhard Fritz; Susanne Strand; Daniela Poppe; Radovan Dvorsky; Dennis Strand; Hans Anton Lehr; Stefan Wirtz; Christoph Becker; Raja Atreya; Jonas Mudter; Kai Hildner; Brigitte Bartsch; Martin Holtmann; Richard Blumberg; Henning Walczak; Heiko Iven; Peter R Galle; Mohammad Reza Ahmadian; Markus F Neurath
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 10.  Clinical pharmacokinetics of mycophenolate mofetil.

Authors:  R E Bullingham; A J Nicholls; B R Kamm
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

View more
  2 in total

1.  Skin and kidney histological changes in graft-versus-host disease (GVHD) after kidney transplantation.

Authors:  Tadeja Pintar; Mario Alessiani; Alojz Pleskovič; Aleš Pleskovič; Ruda Zorc-Pleskovič; Aleksandra Milutinović
Journal:  Bosn J Basic Med Sci       Date:  2011-05       Impact factor: 3.363

2.  The Efficacy and Safety of Mizoribine versus Mycophenolate Mofetil for the Treatment of Renal Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Jie Chen; Hua Liu; Wenjun Yin; Zhengguang Xu; Zekai Chen; Wingkeung Yiu
Journal:  Comput Intell Neurosci       Date:  2022-07-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.